1. Home
  2. MMSI vs ACAD Comparison

MMSI vs ACAD Comparison

Compare MMSI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMSI

Merit Medical Systems Inc.

HOLD

Current Price

$67.83

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.53

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMSI
ACAD
Founded
1987
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.8B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
MMSI
ACAD
Price
$67.83
$21.53
Analyst Decision
Strong Buy
Buy
Analyst Count
8
22
Target Price
$98.88
$30.55
AVG Volume (30 Days)
692.0K
1.2M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
4.93
69.12
EPS
0.68
0.02
Revenue
$1,515,906,000.00
$726,437,000.00
Revenue This Year
$8.85
$18.80
Revenue Next Year
$5.88
$11.70
P/E Ratio
$99.28
$1,092.00
Revenue Growth
11.75
40.45
52 Week Low
$59.74
$19.69
52 Week High
$96.74
$28.35

Technical Indicators

Market Signals
Indicator
MMSI
ACAD
Relative Strength Index (RSI) 61.55 48.91
Support Level $66.76 $21.04
Resistance Level $71.68 $22.03
Average True Range (ATR) 1.76 0.59
MACD 0.76 0.06
Stochastic Oscillator 95.64 62.82

Price Performance

Historical Comparison
MMSI
ACAD

About MMSI Merit Medical Systems Inc.

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: